Matt Cravets

Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies

Edward Keystone, Paul Emery, Charles Peterfy et al. · Annals of the Rheumatic Diseases · 2008 · 240 citations · Full text

Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial

Jeffrey A. Cohen, Douglas L. Arnold, Amit Bar‐Or et al. · The Lancet Neurology · 2016 · 176 citations

Medicine, Pharmacology, Clinical Trials +7

An open-label, 6-month study of allopurinol safety in gout: The LASSO study

Michael A. Becker, David Fitzpatrick, Hyon K. Choi et al. · Seminars in Arthritis and Rheumatism · 2015 · 106 citations · Full text

Improvement in patient‐reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti–tumor necrosis factor therapy

Edward Keystone, Gerd R Burmester, R. Furie et al. · Arthritis Care & Research · 2008 · 104 citations

Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate

Stanley Cohen, Edward Keystone, Mark C. Genovese et al. · Annals of the Rheumatic Diseases · 2010 · 100 citations · Full text